U.S. markets closed
  • S&P 500

    4,662.85
    +3.82 (+0.08%)
     
  • Dow 30

    35,911.81
    -201.79 (-0.56%)
     
  • Nasdaq

    14,893.75
    +86.95 (+0.59%)
     
  • Russell 2000

    2,162.46
    +3.02 (+0.14%)
     
  • Crude Oil

    84.95
    +1.13 (+1.35%)
     
  • Gold

    1,816.30
    -0.20 (-0.01%)
     
  • Silver

    22.91
    -0.01 (-0.06%)
     
  • EUR/USD

    1.1399
    -0.0012 (-0.10%)
     
  • 10-Yr Bond

    1.7720
    +0.0610 (+3.57%)
     
  • GBP/USD

    1.3632
    -0.0015 (-0.11%)
     
  • USD/JPY

    114.9220
    +0.3420 (+0.30%)
     
  • BTC-USD

    42,029.50
    -806.08 (-1.88%)
     
  • CMC Crypto 200

    1,008.17
    -17.56 (-1.71%)
     
  • FTSE 100

    7,611.23
    +68.28 (+0.91%)
     
  • Nikkei 225

    28,491.93
    +158.41 (+0.56%)
     

Zimmer Biomet Announces Third Quarter 2021 Financial Results

  • Oops!
    Something went wrong.
    Please try again later.
·12 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

- Third quarter net sales of $1.924 billion decreased 0.3% and 0.8% on a constant currency[1] basis

- Third quarter diluted earnings per share were $0.69; adjusted1 diluted earnings per share were $1.81

- Company updates 2021 financial guidance, reducing and narrowing range for full year outlook

WARSAW, Ind., Nov. 4, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2021. The Company reported third quarter net sales of $1.924 billion, a decrease of 0.3% from the prior year period, and a decrease of 0.8% on a constant currency basis. Third quarter 2021 net sales increased 1.7% when compared to the pre-pandemic third quarter 2019, and increased 0.4% on a constant currency basis. Net earnings for the third quarter of 2021 were $145.6 million, or $381.2 million on an adjusted basis.

(PRNewsfoto/Zimmer Biomet Holdings, Inc.)
(PRNewsfoto/Zimmer Biomet Holdings, Inc.)

Diluted earnings per share were $0.69 for the third quarter, and adjusted diluted earnings per share were $1.81.

"Despite the continued challenges and market pressures in the third quarter, we drove significant progress in the advancement of our business priorities and continued focus on execution to create value and deliver on our mission," said Bryan Hanson, Chairman, President and CEO of Zimmer Biomet. "Our underlying business remains strong, fueled by our transformation and the launch of new innovative products that can make a difference for our customers and for patients. I continue to be incredibly proud of our team for their dedication, resilience and performance during this challenging time."

Please see the attached schedules accompanying this press release for additional details on performance in the quarter, including sales by Zimmer Biomet's three geographies and five product categories.

________________________

1

Reconciliations of these measures to the corresponding U.S. generally accepted accounting principles measures are included in this press release.

Recent Highlights

Aligned with the ongoing transformation of Zimmer Biomet's business, key third quarter highlights include the following updates related to ZBEdge, Zimmer Biomet's suite of integrated digital and robotic technologies engineered to deliver data-powered clinical insights, shared seamlessly across the patient journey, and with the goal of improving patient outcomes:

Geographic and Product Category Sales

The following sales tables provide results by geography and product category for the three and nine-month periods ended September 30, 2021, as well as the percentage change compared to the prior year period, on both a reported basis and a constant currency basis.

NET SALES - THREE MONTHS ENDED SEPTEMBER 30, 2021

(in millions, unaudited)































Constant



Net






Currency



Sales


% Change



% Change


Geographic Results











Americas

$

1,180.5



(3.0)

%



(3.2)

%

EMEA


393.1



7.4




5.9


Asia Pacific


350.4



1.1




0.5


Total

$

1,924.0



(0.3)

%



(0.8)

%

Product Categories











Knees











Americas

$

386.3



(3.5)

%



(3.8)

%

EMEA


135.2



7.1




5.8


Asia Pacific


126.4



3.8




2.4


Total


647.9



(0.1)




(0.7)


Hips











Americas


244.2



(9.1)




(9.4)


EMEA


119.0



8.6




7.3


Asia Pacific


90.6



(14.4)




(13.8)


Total


453.8



(6.3)




(6.6)


S.E.T. *


437.6



4.9




4.2


Dental & Spine


238.6



(5.8)




(6.1)


Other


146.1



15.7




15.4


Total

$

1,924.0



(0.3)

%



(0.8)

%























* Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic

NET SALES - NINE MONTHS ENDED SEPTEMBER 30, 2021

(in millions, unaudited)































Constant



Net






Currency



Sales



% Change


% Change


Geographic Results











Americas

$

3,535.1




15.8

%


15.5

%

EMEA


1,207.1




22.8



16.0


Asia Pacific


1,056.1




16.7



12.4


Total

$

5,798.3




17.4

%


15.0

%

Product Categories











Knees











Americas

$

1,145.4




14.6

%


14.3

%

EMEA


415.1




20.6



14.2


Asia Pacific


367.3




19.0



13.7


Total


1,927.8




16.7



14.1


Hips











Americas


737.5




9.8



9.3


EMEA


349.2




19.7



13.4


Asia Pacific


288.7




2.1



(0.4)


Total


1,375.4




10.3



8.1


S.E.T. *


1,317.3




20.8



18.3


Dental & Spine


748.1




19.7



17.8


Other


429.7




32.3



29.9


Total

$

5,798.3




17.4

%


15.0

%























* Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic

Financial Guidance

The Company is updating its full-year 2021 financial guidance to reduce and narrow its previous projected ranges for revenue growth, adjusted operating profit margin and adjusted diluted EPS:

Projected Year Ending December 31, 2021


Previous Guidance


Updated Guidance

2021 reported revenue growth

14.5% - 16.5%


11.3% - 12.5%

Foreign Currency Exchange Impact

1.5%


1.4%

Adjusted Operating Profit Margin(1)

26.5% - 27.0%


26.0% - 26.5%

Adjusted Tax Rate(1)

16.0% - 16.5%


16.0% - 16.5%

Adjusted Diluted EPS(1)

$7.65 - $7.95


$7.32 - $7.47

(1)

These measures are non-GAAP financial measures for which a reconciliation to the most directly comparable GAAP financial measure is not available without unreasonable efforts. See "Forward-Looking Non-GAAP Financial Measures."

Conference Call

The Company will conduct its third quarter investor conference call today, November 4, 2021, at 8:30 a.m. ET. The audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be archived for replay following the conference call.

About the Company

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Website Information

We routinely post important information for investors on our website, www.zimmerbiomet.com, in the "Investor Relations" section. We use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our website or any other website referenced herein is not incorporated by reference into, and is not a part of, this document.

Note on Non-GAAP Financial Measures

This press release includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP.

Sales change information for the three and nine-month periods ended September 30, 2021 is presented on a GAAP (reported) basis and on a constant currency basis. Constant currency percentage changes exclude the effects of foreign currency exchange rates. They are calculated by translating current and prior-period sales at the same predetermined exchange rate. The translated results are then used to determine year-over-year percentage increases or decreases.

Net earnings and diluted earnings per share for the three and nine-month periods ended September 30, 2021 are presented on a GAAP (reported) basis and on an adjusted basis. Adjusted earnings and adjusted diluted earnings per share exclude the effects of certain items, which are detailed in the reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures presented later in this press release.

Free cash flow is an additional non-GAAP measure that is presented in this press release. Free cash flow is computed by deducting additions to instruments and other property, plant and equipment from net cash provided by operating activities.

Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this press release. This press release also contains supplemental reconciliations of additional non-GAAP financial measures that the Company presents in other contexts. These additional non-GAAP financial measures are computed from the most directly comparable GAAP financial measure as indicated in the applicable reconciliation.

Management uses non-GAAP financial measures internally to evaluate the performance of the business. Additionally, management believes these non-GAAP measures provide meaningful incremental information to investors to consider when evaluating the performance of the Company. Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported income but that do not impact the fundamentals of our operations. The non-GAAP measures enable the evaluation of operating results and trend analysis by allowing a reader to better identify operating trends that may otherwise be masked or distorted by these types of items that are excluded from the non-GAAP measures. In addition, constant currency sales changes, adjusted operating profit, adjusted diluted earnings per share and free cash flow are used as performance metrics in our incentive compensation programs.

Forward-Looking Non-GAAP Financial Measures

This press release also includes certain forward-looking non-GAAP financial measures for the year ending December 31, 2021. We calculate forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, we exclude the impact of certain charges related to initial compliance with the European Union Medical Device Regulation; restructuring and other cost reduction initiatives; quality remediation; acquisition, integration, divestiture and related; and certain legal and tax matters. We have not provided quantitative reconciliations of these forward-looking non-GAAP financial measures to the most directly comparable forward-looking GAAP financial measures because the excluded items are not available on a prospective basis without unreasonable efforts. For example, the timing of certain transactions is difficult to predict because management's plans may change. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. It is probable that these forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding financial guidance, the impact of the COVID-19 pandemic on our business, including any continued recovery, and any statements about our forecasts, expectations, plans, intentions, strategies or prospects. All statements other than statements of historical or current fact are, or may be deemed to be, forward-looking statements. Such statements are based upon the current beliefs, expectations and assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. These risks, uncertainties and changes in circumstances include, but are not limited to: the effects of the COVID-19 global pandemic and other adverse public health developments on the global economy, our business and operations and the business and operations of our suppliers and customers, including the deferral of elective surgical procedures and our ability to collect accounts receivable; the failure of vaccine rollouts and other strategies to mitigate or reverse the impacts of the COVID-19 pandemic; the failure of elective surgical procedures to recover at the levels or on the timeline anticipated; the risks and uncertainties related to our ability to successfully execute our restructuring plans; our ability to attract, retain and develop the highly skilled employees we need to support our business; the risks and uncertainties associated with the proposed spin-off of our Spine and Dental businesses, including, without limitation, the significant expenses, time and efforts related to implementing such transaction, the ability to complete the transaction on our expected timeline or at all, the tax-free nature of the transaction, possible disruptions in our relationships with customers, suppliers and other business partners, and the possibility that the anticipated benefits and synergies of the transaction, strategic and competitive advantages of each company, and future growth and other opportunities for each company will not be realized within the expected time periods or at all; the success of our quality and operational excellence initiatives, including ongoing quality remediation efforts at our Warsaw North Campus facility; the ability to remediate matters identified in inspectional observations or warning letters issued by the U.S. Food and Drug Administration (FDA), while continuing to satisfy the demand for our products; the impact of substantial indebtedness on our ability to service our debt obligations and/or refinance amounts outstanding under our debt obligations at maturity on terms favorable to us, or at all; the ability to retain the independent agents and distributors who market our products; dependence on a limited number of suppliers for key raw materials and outsourced activities; the possibility that the anticipated synergies and other benefits from mergers and acquisitions will not be realized, or will not be realized within the expected time periods; the risks and uncertainties related to our ability to successfully integrate the operations, products, employees and distributors of acquired companies; the effect of the potential disruption of management's attention from ongoing business operations due to integration matters related to mergers and acquisitions; the effect of mergers and acquisitions on our relationships with customers, suppliers and lenders and on our operating results and businesses generally; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the FDA and foreign government regulators, such as more stringent requirements for regulatory clearance of products; the outcome of government investigations; competition; pricing pressures; changes in customer demand for our products and services caused by demographic changes or other factors; the impact of healthcare reform measures; reductions in reimbursement levels by third-party payors and cost containment efforts sponsored by government agencies, legislative bodies, the private sector and healthcare purchasing organizations, including the volume-based procurement process in China; dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products; control of costs and expenses; the ability to obtain and maintain adequate intellectual property protection; breaches or failures of our information technology systems or products, including by cyberattack, unauthorized access or theft; the ability to form and implement alliances; changes in tax obligations arising from tax reform measures, including European Union rules on state aid, or examinations by tax authorities; product liability, intellectual property and commercial litigation losses; changes in general industry and market conditions, including domestic and international growth rates; changes in general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; and the impact of the ongoing financial and political uncertainty on countries in EMEA on the ability to collect accounts receivable in affected countries. A further list and description of these risks and uncertainties and other factors can be found in our Annual Report on Form 10-K for the year ended December 31, 2020, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and our subsequent filings with the Securities and Exchange Commission (SEC). Copies of these filings are available online at www.sec.gov, www.zimmerbiomet.com or on request from us. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in our filings with the SEC. Forward-looking statements speak only as of the date they are made, and we expressly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this press release are cautioned not to rely on these forward-looking statements since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this press release.



ZIMMER BIOMET HOLDINGS, INC.


CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS


FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2021 and 2020


(in millions, except per share amounts, unaudited)











2021



2020


Net Sales

$

1,924.0



$

1,929.3


Cost of products sold, excluding intangible asset amortization


581.5




569.4


Intangible asset amortization


153.7




149.7


Research and development


108.9




85.9


Selling, general and administrative


802.4




790.0


Restructuring and other cost reduction initiatives


23.5




16.2


Quality remediation


11.8




9.8


Acquisition, integration, divestiture and related


27.3




9.1


Operating expenses


1,709.1




1,630.1


Operating Profit


214.9




299.2


Other income, net


0.3




10.6


Interest expense, net


(52.6)




(54.0)


Earnings before income taxes


162.6




255.8


Provision for income taxes


16.8




9.7


Net Earnings


145.8




246.1


Less: Net earnings attributable to noncontrolling interest


0.2




3.6


Net Earnings of Zimmer Biomet Holdings, Inc.

$

145.6



$

242.5


Earnings Per Common Share








Basic

$

0.70



$

1.17


Diluted

$

0.69



$

1.16


Weighted Average Common Shares Outstanding








...

Basic


208.8




207.1


Diluted


210.6




208.5











ZIMMER BIOMET HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 and 2020

(in millions, except per share amounts, unaudited)










2021



2020


Net Sales

$

5,798.3



$

4,939.2


Cost of products sold, excluding intangible asset amortization


1,679.5




1,481.0


Intangible asset amortization


463.8




445.0


Research and development


383.8




272.0


Selling, general and administrative


2,389.9




2,283.9


Goodwill and intangible asset impairment


16.3




645.0


Restructuring and other cost reduction initiatives


64.9




89.2


Quality remediation


33.0




35.9


Acquisition, integration, divestiture and related


66.1




15.7


Operating expenses


5,097.3




5,267.7


Operating Profit (Loss)


701.0




(328.5)


Other income, net


15.7




17.4


Interest expense, net


(159.6)




(158.9)


Earnings (loss) before income taxes


557.1




(470.0)


Provision for income taxes


71.1




1.2


Net Earnings (Loss)


486.0




(471.2)


Less: Net earnings attributable to noncontrolling interest


0.4




1.4


Net Earnings (Loss) of Zimmer Biomet Holdings, Inc.

$

485.6



$

(472.6)


Earnings (Loss) Per Common Share








Basic

$

2.33



$

(2.29)


Diluted

$